Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics

Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disord...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Simon J MacKenzie [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2004

Schlagwörter:	A-kinase anchoring protein (AKAP) P-arrestin phosphodiesterase 4 phosphodiesterase inhibitors Src tyrosine kinase

Übergeordnetes Werk:	In: Allergology International - Elsevier, 2002, 53(2004), 2, Seite 101-110
Übergeordnetes Werk:	volume:53 ; year:2004 ; number:2 ; pages:101-110

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1111/j.1323-8930.2004.00318.x

Katalog-ID:	DOAJ04652200X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ04652200X
003	DE-627
005	20230501180240.0
007	cr uuu---uuuuu
008	230227s2004 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1111/j.1323-8930.2004.00318.x \|2 doi
035			\|a (DE-627)DOAJ04652200X
035			\|a (DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC581-607
100	0		\|a Simon J MacKenzie \|e verfasserin \|4 aut
245	1	0	\|a Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics
264		1	\|c 2004
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades.
650		4	\|a A-kinase anchoring protein (AKAP)
650		4	\|a P-arrestin
650		4	\|a phosphodiesterase 4
650		4	\|a phosphodiesterase inhibitors
650		4	\|a Src tyrosine kinase
653		0	\|a Immunologic diseases. Allergy
773	0	8	\|i In \|t Allergology International \|d Elsevier, 2002 \|g 53(2004), 2, Seite 101-110 \|w (DE-627)320425320 \|w (DE-600)2003098-8 \|x 14401592 \|7 nnns
773	1	8	\|g volume:53 \|g year:2004 \|g number:2 \|g pages:101-110
856	4	0	\|u https://doi.org/10.1111/j.1323-8930.2004.00318.x \|z kostenfrei
856	4	0	\|u https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S1323893015311047 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1323-8930 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 53 \|j 2004 \|e 2 \|h 101-110

Indexfelder

author_variant	s j m sjm
matchkey_str	article:14401592:2004----::hshdetrs4aphshdetrsssagtfroeati
hierarchy_sort_str	2004
callnumber-subject-code	RC
publishDate	2004
allfields	10.1111/j.1323-8930.2004.00318.x doi (DE-627)DOAJ04652200X (DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86 DE-627 ger DE-627 rakwb eng RC581-607 Simon J MacKenzie verfasserin aut Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades. A-kinase anchoring protein (AKAP) P-arrestin phosphodiesterase 4 phosphodiesterase inhibitors Src tyrosine kinase Immunologic diseases. Allergy In Allergology International Elsevier, 2002 53(2004), 2, Seite 101-110 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:53 year:2004 number:2 pages:101-110 https://doi.org/10.1111/j.1323-8930.2004.00318.x kostenfrei https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893015311047 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 53 2004 2 101-110
spelling	10.1111/j.1323-8930.2004.00318.x doi (DE-627)DOAJ04652200X (DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86 DE-627 ger DE-627 rakwb eng RC581-607 Simon J MacKenzie verfasserin aut Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades. A-kinase anchoring protein (AKAP) P-arrestin phosphodiesterase 4 phosphodiesterase inhibitors Src tyrosine kinase Immunologic diseases. Allergy In Allergology International Elsevier, 2002 53(2004), 2, Seite 101-110 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:53 year:2004 number:2 pages:101-110 https://doi.org/10.1111/j.1323-8930.2004.00318.x kostenfrei https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893015311047 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 53 2004 2 101-110
allfields_unstemmed	10.1111/j.1323-8930.2004.00318.x doi (DE-627)DOAJ04652200X (DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86 DE-627 ger DE-627 rakwb eng RC581-607 Simon J MacKenzie verfasserin aut Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades. A-kinase anchoring protein (AKAP) P-arrestin phosphodiesterase 4 phosphodiesterase inhibitors Src tyrosine kinase Immunologic diseases. Allergy In Allergology International Elsevier, 2002 53(2004), 2, Seite 101-110 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:53 year:2004 number:2 pages:101-110 https://doi.org/10.1111/j.1323-8930.2004.00318.x kostenfrei https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893015311047 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 53 2004 2 101-110
allfieldsGer	10.1111/j.1323-8930.2004.00318.x doi (DE-627)DOAJ04652200X (DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86 DE-627 ger DE-627 rakwb eng RC581-607 Simon J MacKenzie verfasserin aut Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades. A-kinase anchoring protein (AKAP) P-arrestin phosphodiesterase 4 phosphodiesterase inhibitors Src tyrosine kinase Immunologic diseases. Allergy In Allergology International Elsevier, 2002 53(2004), 2, Seite 101-110 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:53 year:2004 number:2 pages:101-110 https://doi.org/10.1111/j.1323-8930.2004.00318.x kostenfrei https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893015311047 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 53 2004 2 101-110
allfieldsSound	10.1111/j.1323-8930.2004.00318.x doi (DE-627)DOAJ04652200X (DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86 DE-627 ger DE-627 rakwb eng RC581-607 Simon J MacKenzie verfasserin aut Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics 2004 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades. A-kinase anchoring protein (AKAP) P-arrestin phosphodiesterase 4 phosphodiesterase inhibitors Src tyrosine kinase Immunologic diseases. Allergy In Allergology International Elsevier, 2002 53(2004), 2, Seite 101-110 (DE-627)320425320 (DE-600)2003098-8 14401592 nnns volume:53 year:2004 number:2 pages:101-110 https://doi.org/10.1111/j.1323-8930.2004.00318.x kostenfrei https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86 kostenfrei http://www.sciencedirect.com/science/article/pii/S1323893015311047 kostenfrei https://doaj.org/toc/1323-8930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 53 2004 2 101-110
language	English
source	In Allergology International 53(2004), 2, Seite 101-110 volume:53 year:2004 number:2 pages:101-110
sourceStr	In Allergology International 53(2004), 2, Seite 101-110 volume:53 year:2004 number:2 pages:101-110
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	A-kinase anchoring protein (AKAP) P-arrestin phosphodiesterase 4 phosphodiesterase inhibitors Src tyrosine kinase Immunologic diseases. Allergy
isfreeaccess_bool	true
container_title	Allergology International
authorswithroles_txt_mv	Simon J MacKenzie @@aut@@
publishDateDaySort_date	2004-01-01T00:00:00Z
hierarchy_top_id	320425320
id	DOAJ04652200X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ04652200X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501180240.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2004 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1323-8930.2004.00318.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ04652200X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Simon J MacKenzie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">A-kinase anchoring protein (AKAP)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">P-arrestin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phosphodiesterase 4</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phosphodiesterase inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Src tyrosine kinase</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Allergology International</subfield><subfield code="d">Elsevier, 2002</subfield><subfield code="g">53(2004), 2, Seite 101-110</subfield><subfield code="w">(DE-627)320425320</subfield><subfield code="w">(DE-600)2003098-8</subfield><subfield code="x">14401592</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:53</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:101-110</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1111/j.1323-8930.2004.00318.x</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1323893015311047</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1323-8930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">53</subfield><subfield code="j">2004</subfield><subfield code="e">2</subfield><subfield code="h">101-110</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Simon J MacKenzie
spellingShingle	Simon J MacKenzie misc RC581-607 misc A-kinase anchoring protein (AKAP) misc P-arrestin misc phosphodiesterase 4 misc phosphodiesterase inhibitors misc Src tyrosine kinase misc Immunologic diseases. Allergy Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics
authorStr	Simon J MacKenzie
ppnlink_with_tag_str_mv	@@773@@(DE-627)320425320
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-607
illustrated	Not Illustrated
issn	14401592
topic_title	RC581-607 Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics A-kinase anchoring protein (AKAP) P-arrestin phosphodiesterase 4 phosphodiesterase inhibitors Src tyrosine kinase
topic	misc RC581-607 misc A-kinase anchoring protein (AKAP) misc P-arrestin misc phosphodiesterase 4 misc phosphodiesterase inhibitors misc Src tyrosine kinase misc Immunologic diseases. Allergy
topic_unstemmed	misc RC581-607 misc A-kinase anchoring protein (AKAP) misc P-arrestin misc phosphodiesterase 4 misc phosphodiesterase inhibitors misc Src tyrosine kinase misc Immunologic diseases. Allergy
topic_browse	misc RC581-607 misc A-kinase anchoring protein (AKAP) misc P-arrestin misc phosphodiesterase 4 misc phosphodiesterase inhibitors misc Src tyrosine kinase misc Immunologic diseases. Allergy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Allergology International
hierarchy_parent_id	320425320
hierarchy_top_title	Allergology International
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)320425320 (DE-600)2003098-8
title	Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics
ctrlnum	(DE-627)DOAJ04652200X (DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86
title_full	Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics
author_sort	Simon J MacKenzie
journal	Allergology International
journalStr	Allergology International
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2004
contenttype_str_mv	txt
container_start_page	101
author_browse	Simon J MacKenzie
container_volume	53
class	RC581-607
format_se	Elektronische Aufsätze
author-letter	Simon J MacKenzie
doi_str_mv	10.1111/j.1323-8930.2004.00318.x
title_sort	phosphodiesterase 4 camp phosphodiesterases as targets for novel anti-inflammatory therapeutics
callnumber	RC581-607
title_auth	Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics
abstract	Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades.
abstractGer	Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades.
abstract_unstemmed	Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics
url	https://doi.org/10.1111/j.1323-8930.2004.00318.x https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86 http://www.sciencedirect.com/science/article/pii/S1323893015311047 https://doaj.org/toc/1323-8930
remote_bool	true
ppnlink	320425320
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1111/j.1323-8930.2004.00318.x
callnumber-a	RC581-607
up_date	2024-07-03T21:07:34.448Z
_version_	1803593558995763200
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ04652200X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501180240.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2004 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1323-8930.2004.00318.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ04652200X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJaf524f5dcd6d48e585e6786fde14da86</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Simon J MacKenzie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cyclic nucleotides are powerful signaling molecules and their sole means of removal is through the action of cyclic nucleotide phosphodiesterases (PDEs). Elevating levels of cAMP is beneficial in many diseases, including neurological conditions, cancers, viral infections and most inflammatory disorders. There are 11 known PDE families, with PDE4 being the most highly expressed. Evidence of the clinical usefulness of PDE4 inhibition has come from the use of specific chemical inhibitors and the generation of knock-out mice models. There exists an extensive range of PDE4 family members, because there are four subfamilies, each encoded by their own gene and each capable of generating multiple isoforms. Several members of the PDE4 family are found to be expressed in every cell and tissue studied and evidence is now being uncovered indicating unique functions for each. Their actions are controlled by their expression patterns, subcellular location and interaction with other signaling pathways. The first generation of PDE4 inhibitors, although potent anti-inflammatory agents, failed as pharmaceuticals owing to their emetic and gastric side-effects. A new generation of chemical inhibitors is now nearing the market, which display greatly reduced side-effects. In the future lies the generation of more specific inhibitors that will focus upon particular diseases. This will be achieved by targeting specific PDE4 family members. Because the current target of chemical inhibition (the catalytic site) is virtually identical between isoforms, this specificity is likely to be achieved by blocking the enzyme's interaction with other signaling cascades.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">A-kinase anchoring protein (AKAP)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">P-arrestin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phosphodiesterase 4</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">phosphodiesterase inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Src tyrosine kinase</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Allergology International</subfield><subfield code="d">Elsevier, 2002</subfield><subfield code="g">53(2004), 2, Seite 101-110</subfield><subfield code="w">(DE-627)320425320</subfield><subfield code="w">(DE-600)2003098-8</subfield><subfield code="x">14401592</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:53</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:101-110</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1111/j.1323-8930.2004.00318.x</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/af524f5dcd6d48e585e6786fde14da86</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1323893015311047</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1323-8930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">53</subfield><subfield code="j">2004</subfield><subfield code="e">2</subfield><subfield code="h">101-110</subfield></datafield></record></collection>
score	7.3985376

Nicht das Richtige dabei?

Schreiben Sie uns!

Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?